An analysis of data available on HealthCare.gov and 12 state-based exchanges while consumers shopped for plans found that sites should take more steps to better support consumers in making informed health plan decisions.
After analyzing the use of HealthCare.gov and 12 state-based exchanges during the first and second open enrollment periods and the data available to consumers before creating an account and after creating an account, researchers from the Perelman School of Medicine at the University of Pennsylvania recommend taking more steps to better support consumers in making informed health plan decisions, according to a letter published in the Annals of Internal Medicine.
The researchers found that while decision tools most likely to be helpful to consumers were more common in the second versus the first period, they still were not universally available.
“Performance of the health insurance marketplaces will significantly depend on such features as the order in which plans are displayed, the plan features listed, and the availability of decision-support tools created for consumers," the study’s lead author Charlene A. Wong, MD, a Robert Wood Johnson Foundation Clinical Scholar and fellow in Penn's Leonard Davis Institute of Health Economics, said in a statement. "While we generally found improvement in the second versus the first open enrollment period, additional measures can and should be added in the future to further improve the selection process for consumers.”
Only 3 states had out-of-pocket cost estimators that added together their premium and expected costs based on consumers’ predicted use while most sites only allowed consumers to sort or filter plans by premium and deductible amounts.
Most states using the premium amount as their default plan order, which may cause consumers’ to be overly influenced by the premium amount while not paying enough attention to other potential out-of-pocket expenses, such as meeting a high deductible, the researchers surmised.
One improvement over the first open enrollment period was that 4 sites had health plan quality rankings in the second open enrollment period compared with just 2 the first year.
“By including more of these tools in both real and ‘window’ shopping stages, marketplaces can help de-mystify what for many is a complex, opaque process,” Dr Wong said.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More
Solving the Transition Conundrum as More Children With Muscular Dystrophy Live to Adulthood
March 17th 2025Learning from examples like congenital heart disease and cystic fibrosis can help health systems and clinicians prepare to care for an influx of patients with neuromuscular diseases as they reach adulthood thanks to transformative therapy advances.
Read More